ASAH1通过DUSP5抑制驱动的MAP激酶通路的激活来促进TNBC,并代表了治疗的脆弱性
Kiran Kumar Reddi1, Suresh Chava1, Siva Chander Chabattula1
1Department of Biochemistry and Molecular Genetics, The University of Alabama at Birmingham, Birmingham, AL, USA.
Cell death & disease
|June 26, 2024
概括
N-乙辛氨基胺基酶1 (ASAH1) 驱动三阴性乳腺癌 (TNBC) 的生长. 抑制ASAH1和MAPK通路为TNBC提供了潜在的新疗法.
科学领域:
- 在瘤学瘤学.
- 生物化学 生物化学
- 分子生物学分子生物学
背景情况:
- 三重阴性乳腺癌 (TNBC) 呈现出侵略性特征,包括转移和耐治疗性,导致死亡率更高.
- 对TNBC存在有限的向疗法,需要研究新的治疗策略.
- 了解TNBC生长和进展的分子驱动因素对于开发有效的治疗方法至关重要.
研究的目的:
- 确定和描述涉及三阴性乳腺癌 (TNBC) 增长和进展的关键因素.
- 调查N-acylsphingosine amidohydrolase 1 (ASAH1) 在TNBC中的作用.
- 探索针对ASAH1和TNBC中相关信号通路的潜在治疗策略.
主要方法:
- 在TNBC细胞中对N-基氨酸胺基酶1 (ASAH1) 的过度表达分析.
- 基因淘汰和药理上抑制ASAH1.1.
- 通过p53和PI3K-AKT信号通路对ASAH1调节的研究.
- 对ASAH1抑制对双特异性酸酶5 (DUSP5) 和基激活蛋白激酶 (MAPK) 途径的影响的评估.
- 对ASAH1和MAPK通路的药理共同向.
主要成果:
- 在三阴性乳腺癌 (TNBC) 细胞中,N-乙烯氨酸胺基酶1 (ASAH1) 过度表达,并通过p53和PI3K-AKT通路进行调节.
- 对ASAH1的遗传或药理抑制显著抑制了TNBC的生长和进展.
- 抑制ASAH1导致DUSP5表达增加,随后抑制MAPK通路.
- 联合抑制ASAH1和MAPK通路在TNBC模型中显示出强大的抗瘤作用.
结论:
- 在驱动三阴性乳腺癌 (TNBC) 的扩散和进展方面,N-基氨酸胺基酶1 (ASAH1) 起着至关重要的作用.
- 向ASAH1代表了TNBC的一个有前途的治疗途径.
- 对ASAH1和MAPK通路的双重向为TNBC治疗提供了一种新且潜在有效的治疗策略.
相关概念视频
Interactions Between Signaling Pathways
6.3K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
MAPK Signaling Cascades
5.4K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.4K
PI3K/mTOR/AKT Signaling Pathway
3.5K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.5K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K


